Gilead challenges Baraclude

Gilead Sciences, Inc., a developer of Viread (tenofovir disoproxil fumarate), is poised to enter the 200 billion won anti-hepatitis B drug market here, which has been dominated by BMS Korea’s Baraclude (entecavir).

Baraclude is an oral antiviral drug used in the treatment of chronic hepatitis B infection. Baraclude is a guanine analogue that inhibits all three steps in the viral replication ...